Redefining Glaucoma Surgery with MIGS
Advances in the development of Micro-Invasive Glaucoma Surgery (MIGS) have brought new excitement to glaucoma treatment. Most commonly used in patients with mild-to-moderate open-angle glaucoma undergoing cataract surgery, MIGS refers to a group of surgical procedures that share the following features.
• Minimal trauma
• High safety profile
• Rapid recovery
MIGS is recognized as a micro-invasive treatment option that can reestablish the eye’s physiological outflow, in order to reduce intraocular pressure (IOP).1
Many physicians agree that restoring physiological outflow is preferable in the majority of patients. Compared to more invasive glaucoma surgeries with high complications and risks prolonged with postoperative recovery, MIGS procedures have minimal morbidity, fast recovery, and few complications.2*
As the corporate founder of MIGS, Glaukos revolutionized the traditional glaucoma treatment and management paradigm with the iStent® Trabecular Micro-Bypass Stent—the first MIGS device approved by the FDA. And with the FDA approval of iStent inject® and now iStent inject® W – the next-generation Glaukos trabecular micro-bypass technology – Glaukos continues to advance the standard of care for glaucoma patients.
*Indications for MIGS are different compared to invasive glaucoma surgeries and do not include patients with advanced disease or patients who require very low unmedicated postoperative IOP.
1. Saheb H. Ahmed II. Micro-invasive glaucoma surgery; current perspectives and future directions. Curr Opin Ophthalmol. 2012; 23(2):96-104.
2. Gedde SJ, Herndon LW, Brandt JD, et al. Postoperative Complications in the Tube Versus Trabeculectomy (TVT) Study During Five Years of Follow-up. Am J Ophthalmol. 2012;153(5):804-814.e1. doi:10.1016/j.ajo.2011.10.024.
Request the iStent inject® W posters presented at ARVO 2021
Five posters presented at ARVO 2021 highlight the efficacy and safety of the iStent platform as compared to other procedures.Request Clinical Information